ANI Pharmaceuticals Price Target Increased to $33.00 by Analysts at Roth Capital (ANIP)
Analysts at Roth Capital lifted their price target on shares of ANI Pharmaceuticals (NASDAQ:ANIP) from $27.00 to $33.00 in a research report issued to clients and investors on Thursday, Analyst RN reports. Roth Capital’s target price points to a potential upside of 17.19% from the company’s current price.
Shares of ANI Pharmaceuticals (NASDAQ:ANIP) traded up 5.04% during mid-day trading on Thursday, hitting $28.16. 496,864 shares of the company’s stock traded hands. ANI Pharmaceuticals has a one year low of $4.80 and a one year high of $29.00. The stock’s 50-day moving average is $22.03 and its 200-day moving average is $13.64. The company’s market cap is $267.0 million.
ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings data on Thursday, February 27th. The company reported $0.35 earnings per share for the quarter. The company had revenue of $10.53 million for the quarter, compared to the consensus estimate of $5.32 million. On average, analysts predict that ANI Pharmaceuticals will post $1.12 earnings per share for the current fiscal year.
A number of other firms have also recently commented on ANIP. Analysts at Oppenheimer raised their price target on shares of ANI Pharmaceuticals from $29.00 to $31.00 in a research note on Wednesday. They now have an “outperform” rating on the stock. Separately, analysts at Zacks downgraded shares of ANI Pharmaceuticals to a “neutral” rating in a research note on Friday, January 24th. They now have a $23.90 price target on the stock.
ANI Pharmaceuticals, Inc, formerly BioSante Pharmaceuticals, Inc, is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.